Orchestra BioMed Holdings, Inc. OBIO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About OBIO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating the development and commercialization of high-impact medical technologies through strategic partnerships with established healthcare companies. The company operates primarily in the cardiovascular and bioelectronic medicine sectors, with a business model centered on advancing proprietary technologies through risk-sharing collaborations rather than building large-scale standalone commercial infrastructure. Orchestra BioMed is publicly traded on Nasdaq under the ticker OBIO.
The company’s principal programs include atrioventricular interval modulation therapy for hypertension management and cardiac disease treatment, as well as sirolimus-angioinfusion technology designed to reduce restenosis following peripheral artery interventions. Its primary revenue drivers have historically included collaboration agreements, licensing arrangements, milestone payments, and related development funding. Orchestra BioMed’s strategic positioning is based on combining clinical-stage innovation with commercialization partnerships involving larger medtech organizations. The company traces its origins to technology development initiatives founded by entrepreneur and physician innovators in the cardiovascular device field and later expanded through mergers, acquisitions, and public market financing transactions.
Business Operations
Orchestra BioMed conducts operations primarily through technology development, clinical advancement, intellectual property management, and strategic partnering activities. Its major programs include the BackBeat Cardiac Neuromodulation Therapy (CNT) platform and the Virtue Sirolimus AngioInfusion Balloon (SAB) technology. The company generates revenue mainly from collaboration and licensing agreements tied to development milestones, reimbursement support, and commercialization arrangements. Public filings indicate that the company has relied significantly on strategic partnerships rather than direct large-scale product sales.
The company’s operations span both the United States and international clinical development markets. Orchestra BioMed maintains strategic relationships with major medical technology firms, including a global collaboration with Medtronic plc related to hypertension treatment technologies and cardiac rhythm management integration. The company also controls intellectual property portfolios covering bioelectronic medicine, drug-device combination therapies, and cardiovascular intervention systems. Clinical studies and regulatory activities have involved multiple regions, including North America and Europe, with development supported through external research organizations, healthcare institutions, and industry partners.
Strategic Position & Investments
Orchestra BioMed’s strategic direction centers on leveraging partnerships to accelerate regulatory approval and commercialization while limiting the capital intensity typically associated with medical device launches. The company has prioritized advancing therapies for hypertension, heart failure, peripheral artery disease, and related cardiovascular conditions that address large unmet clinical needs. Its growth initiatives include expanding clinical evidence generation, pursuing regulatory approvals, and integrating device technologies with existing implantable cardiac systems.
A major strategic milestone was the collaboration with Medtronic plc to advance the BackBeat CNT platform, which combines pacemaker-based neuromodulation with hypertension management capabilities. Orchestra BioMed has also continued investment in the Virtue SAB platform for peripheral artery disease treatment, targeting markets where restenosis remains a significant challenge. Publicly available disclosures and investor materials indicate continued focus on bioelectronic medicine and combination device-drug technologies as emerging healthcare sectors with long-term commercial potential. Data regarding additional undisclosed investments or portfolio holdings is inconclusive based on available public sources.
Geographic Footprint
Orchestra BioMed is headquartered in New Hope, Pennsylvania, United States, and operates primarily within the North American medical technology ecosystem while maintaining international clinical and strategic collaboration activities. The company’s development programs have involved clinical trial sites, regulatory engagement, and commercialization planning across the United States, Europe, and selected international healthcare markets.
Its strategic partnerships provide broader global reach than its direct operational footprint alone. Through collaborations with multinational medical technology companies, Orchestra BioMed’s technologies are positioned for potential deployment across multiple continents, including North America, Europe, and parts of Asia-Pacific. The company’s international influence is tied primarily to licensing, clinical development, and commercialization partnerships rather than large independent overseas operating divisions.
Leadership & Governance
Orchestra BioMed’s leadership team combines experience in medical technology innovation, cardiovascular medicine, biotechnology finance, and healthcare commercialization. The company’s governance structure reflects a strategic emphasis on partnership-driven growth, intellectual property development, and clinically differentiated cardiovascular therapies. Public statements and corporate filings consistently emphasize disciplined capital allocation, regulatory execution, and collaboration with established medtech organizations as central elements of management strategy.
Key executives include:
- David Hochman – Chairman and Chief Executive Officer
- Darren R. Sherman – Executive Vice President and Chief Financial Officer
- Anoop Gupta, M.D. – Chief Medical Officer
- Ami Bhatt – Chief Business Officer
- David P. O’Reilly – General Counsel and Corporate Secretary
Leadership disclosures in SEC filings, investor presentations, and corporate governance materials indicate that management’s strategic vision is focused on advancing high-value cardiovascular therapies through partnership-enabled commercialization models and evidence-driven clinical development.